| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
|
Medicine details |
|
| Medicine name | olaparib (Lynparza®) |
| Formulation | 50 mg capsule |
| Reference number | 226 |
| Indication | Monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/03/2015 |
| NICE guidance | |
| Commercial arrangement | PAS + CAA |